We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Benign Hematology

Journal Scan / Research · September 14, 2022

Pegcetacoplan vs Eculizumab in Patients With Paroxysmal Nocturnal Haemoglobinuria

The Lancet Haematology


Additional Info

The Lancet Haematology
Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial
Lancet Haematol 2022 Sep 01;9(9)e648-e659, RP de Latour, J Szer, IC Weitz, A Röth, B Höchsmann, J Panse, K Usuki, M Griffin, JJ Kiladjian, CM de Castro, H Nishimori, T Ajayi, M Al-Adhami, P Deschatelets, C Francois, F Grossi, AM Risitano, P Hillmen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading